Loading clinical trials...

TERMINATEDNCT03547297

INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Presentation and History Consistent With AHP

This study will use specific diagnostic tests on a group of patients who are experiencing symptoms typical of acute hepatic porphyria (AHP) to determine how many have the condition, and to potentially...

Lead sponsor: Alnylam Pharmaceuticals•12 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Related studies

RECRUITING

ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)

NCT04883905 · Acute Hepatic Porphyria

COMPLETED

Prevalence of Acute Hepatic Porphyria

NCT04923516 · Acute Hepatic Porphyria

Approved For Marketing

Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria

NCT04056481 · Acute Hepatic Porphyria

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 25, 2019Terms

Trial snapshot

StatusTERMINATED

Phase—

Enrollment212

Start dateMay 2018

Last updatedJan 25, 2019

Condition

Acute Hepatic Porphyria Hepatic Porphyrias Acute Intermittent Porphyria (AIP)Hereditary Coproporphyria (HCP)Variegate Porphyria (VP)+2 more

Locations shown

Clinical Trial Site

Pasadena, California

Clinical Trial Site

Jacksonville, Florida

Clinical Trial Site

Margate, Florida

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 25, 2019Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Presentation and History Consistent With AHP

What this study is about

Clareo turns complex medical information into clear understanding you can use.

Sponsors

Related studies

ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)

Prevalence of Acute Hepatic Porphyria

Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria

Trial snapshot

Condition

Locations shown

For caregivers